PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced that Affymax management will host a conference call and webcast at 5:00 p.m. Eastern Time today. The call will discuss the joint Affymax and Takeda decision to focus all development efforts for Hematide™ on the treatment of anemia associated with chronic kidney disease and to suspend co-development of Hematide™ to treat chemotherapy-induced anemia.
